Literature DB >> 6802258

Reduced amyloid-A-degrading activity in serum in amyloidosis associated with rheumatoid arthritis.

O Wegelius, A M Teppo, C P Maury.   

Abstract

The ability to degrade amyloid A fibrils was studied in the serum of 31 patients with amyloidosis associated with rheumatoid arthritis, 33 patients with rheumatoid arthritis without amyloidosis, and 47 healthy controls. Fibrillar amyloid A protein and the radial diffusion method were used. The mean degrading activity in serum was significantly lower in patients with rheumatoid arthritis complicated by amyloidosis (58 +/- 19% SD of the activity in a pooled sample of sera from 100 healthy blood donors used as standard) than in patients with rheumatoid arthritis alone (78 +/- 14%; p less than 0.001) or controls (99 +/- 19%; p less than 0.001). Alpha 1-antitrypsin, concentrations of which were raised in both groups of patients, inhibited the degrading activity in serum even in low concentrations. A negative correlation between degrading activity and alpha 1-antitrypsin concentrations was observed. These findings suggest that reduced amyloid-A-degrading activity is due to inhibition rather than to deficiency of enzyme.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6802258      PMCID: PMC1496206          DOI: 10.1136/bmj.284.6316.617

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  11 in total

1.  Amyloid-related serum component (SAA)--studies in acute infections, medullary thyroid carcinoma, and postsurgery.

Authors:  P D Gorevic; C J Rosenthal; E C Franklin
Journal:  Clin Immunol Immunopathol       Date:  1976-07

2.  X-ray diffraction studies on amyloid filaments.

Authors:  E D Eanes; G G Glenner
Journal:  J Histochem Cytochem       Date:  1968-11       Impact factor: 2.479

3.  Serum amyloid A protein in amyloidosis, rheumatic, and enoplastic diseases.

Authors:  M D Benson; A S Cohen
Journal:  Arthritis Rheum       Date:  1979-01

4.  Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation.

Authors:  K P McAdam; R J Elin; J D Sipe; S M Wolff
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

5.  Monokine-induced synthesis of serum amyloid A protein by hepatocytes.

Authors:  M J Selinger; K P McAdam; M M Kaplan; J D Sipe; S N Vogel; D L Rosenstreich
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

6.  Chemical classes of amyloid substance.

Authors:  E P Benditt; N Eriksen
Journal:  Am J Pathol       Date:  1971-10       Impact factor: 4.307

7.  A serum component related to nonimmunoglobulin amyloid protein AS, a possible precursor of the fibrils.

Authors:  G Husby; J B Natvig
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

8.  The characterization of soluble amyloid prepared in water.

Authors:  M Pras; M Schubert; D Zucker-Franklin; A Rimon; E C Franklin
Journal:  J Clin Invest       Date:  1968-04       Impact factor: 14.808

9.  Variation with age and disease of an amyloid A protein-related serum component.

Authors:  C J Rosenthal; E C Franklin
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

10.  Degradation of serum amyloid A protein by surface-associated enzymes of human blood monocytes.

Authors:  G Lavie; D Zucker-Franklin; E C Franklin
Journal:  J Exp Med       Date:  1978-10-01       Impact factor: 14.307

View more
  8 in total

1.  Psychiatric morbidity after screening for breast cancer.

Authors:  C Dean; M M Roberts; K French; S Robinson
Journal:  J Epidemiol Community Health       Date:  1986-03       Impact factor: 3.710

Review 2.  Reactive (secondary) amyloidosis and its pathogenesis.

Authors:  C P Maury
Journal:  Rheumatol Int       Date:  1984       Impact factor: 2.631

3.  Impaired degradation of serum amyloid A (SAA) protein by cytokine-stimulated monocytes.

Authors:  K Migita; S Yamasaki; K Shibatomi; H Ida; M Kita; A Kawakami; K Eguchi
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

4.  'Amyloid degrading activity' of human serum, an in vitro clearing effect which does not involve degradation of amyloid fibrils.

Authors:  D Caspi; M L Baltz; A Feinstein; E A Munn; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  The failure of ascorbic acid therapy to alter the induction or remission of murine amyloidosis.

Authors:  M L Baltz; D Caspi; B E Glatthaar; U Moser; M B Pepys
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

6.  Serologic evaluation of clinical and subclinical secondary hepatic amyloidosis in rhesus macaques (Macaca mulatta).

Authors:  Jamus G MacGuire; Kari L Christe; JoAnn L Yee; Alexis L Kalman-Bowlus; Nicholas W Lerche
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

7.  Diagnosis of amyloidosis and differentiation from chronic, idiopathic enterocolitis in rhesus (Macaca mulatta) and pig-tailed (M. nemestrina) macaques.

Authors:  Kelly A Rice; Edward S Chen; Kelly A Metcalf Pate; Eric K Hutchinson; Robert J Adams
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

8.  Correlation of persistently high serum amyloid A protein and C-reactive protein concentrations with rapid progression of secondary amyloidosis.

Authors:  H M Falck; C P Maury; A M Teppo; O Wegelius
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.